Scientists at the USC Stem Cell research center found that inhaling high doses of carbon dioxide may clear proteins linked to Alzheimer's disease.

This discovery suggests a potential non-invasive method to remove toxic buildup in the brain, offering a new avenue for treating neurodegenerative diseases that currently have limited options for reversing protein damage.

The researchers said that intermittently inhaling a high dose of carbon dioxide for approximately 30 minutes [1] appears to clear amyloid and tau proteins from the brain. These specific proteins are hallmarks of Alzheimer's disease and are associated with cognitive decline.

According to the study, the process works by boosting the glymphatic clearance system. This system acts as the brain's waste disposal mechanism. The exposure to CO2 changes how cerebral blood vessels constrict and dilate, a process that mimics the activity occurring during deep sleep.

By simulating this sleep-like state, the treatment turbo-charges the glymphatic system to remove waste proteins more efficiently. The research was conducted in a laboratory setting at the University of Southern California (USC) Stem Cell research center.

The study was reported in 2025 [2], though the findings continue to be analyzed by the scientific community this month. The method focuses on the physical movement of fluids and vessels rather than using pharmaceutical drugs to target proteins directly.

While the results are promising, the study remains small in scale. Further research is required to determine if the effects are sustainable in humans and to establish the safety parameters for high-dose CO2 inhalation.

“Inhaling a high dose of carbon dioxide for about 30 minutes appears to clear amyloid and tau proteins from the brain.”

This research shifts the focus from chemically breaking down plaques to mechanically flushing them out. By leveraging the glymphatic system, which typically only functions at peak efficiency during deep sleep, scientists may have found a way to trigger brain detoxification on demand. If validated in larger human trials, this could provide a complementary therapy to existing Alzheimer's treatments.